title: Use of 0.1% chlorine dioxide to inhibit the formation of morning volatile sulphur compounds (VSC).
abstract: The aim of this study was to evaluate the VSC-inhibiting effect of a commercially available mouthrinse (0.1% chlorine dioxide) when compared to its placebo. A 2-step double blind, crossover, randomised study was conducted with 14 dental students with healthy periodontium, who refrained from any mechanical plaque and tongue coating control during two 4-day experimental periods. The subjects were instructed to rinse 3 times daily with the assigned product during each period. A 7-day washout interval was established. VSCs levels were measured by a sulphide monitor at the beginning (baseline) and at the end of each experimental period. Statistical analyses were performed using Wilcoxon's and Mann-Whitney's non-parametric tests. At baseline, intragroup analysis revealed that VSCs levels did not differ between groups (p > 0.05); at day 5, the use of the chlorine dioxide mouthrinse did not change the baseline VSCs scores in the control group (p > 0.05), while a 2-fold increase was observed with the use of the placebo mouthrinse (p < 0.05). Intergroup analysis showed a significant difference between the VSCs levels of the test and control groups (40.2 +/- 30.72 and 82.3 +/- 75.63 ppb, p < 0.001) at day 5. Within the limits of this study, the findings suggest that a mouthrinse containing chlorine dioxide can maintain VSCs at lower levels in the morning breath.
authors: Bahia Foundation for the Development of Sciences, Department of Prosthodontics and Periodontics, School of Dentistry, State University of Campinas, Av. Evandro Batista Vieira 775/13, Campinas, SP, Brazil, CEP 13098-390. daiaperuzzo@yahoo.com.br
authors: Daiane Cristina
authors: DC
authors: Peruzzo
authors: Priscila Fontoura Castelo Branco
authors: PF
authors: Jandiroba
authors: Getulio da Rocha
authors: Gda R
authors: Nogueira Filho
mesh_terms: D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D017606:Chlorine Compounds / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000517:prevention & control; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006209:Halitosis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D010919:Placebos; D013457:Sulfur Compounds / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000891:Anti-Infective Agents, Local; D017606:Chlorine Compounds; D004338:Drug Combinations; D010087:Oxides; D010919:Placebos; D013457:Sulfur Compounds; C025109:chlorine dioxide